Cargando…

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA

BH3 mimetic compounds induce tumor cell death through targeted inhibition of anti-apoptotic BCL2 proteins. Resistance to one such compound, ABT-737, is due to increased levels of anti-apoptotic MCL1. Using chemical and genetic approaches, we show that resistance to ABT-737 is abrogated by inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subramanian, Aishwarya, Andronache, Adrian, Li, Yao-Cheng, Wade, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941292/ https://www.ncbi.nlm.nih.gov/pubmed/26910119 http://dx.doi.org/10.18632/oncotarget.7558

Ejemplares similares

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
por: Vera, Mariana Belén, et al.
Publicado: (2022)

MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment
por: Haschka, Manuel D., et al.
Publicado: (2020)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex
por: Djajawi, Tirta Mario, et al.
Publicado: (2020)

MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation
por: Arai, Seiji, et al.
Publicado: (2020)

Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
por: Choudhary, Gaurav S., et al.
Publicado: (2015)

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
por: Séveno, Céline, et al.
Publicado: (2012)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

MCL-1 Inhibition by Selective BH3 Mimetics Disrupts Mitochondrial Dynamics Causing Loss of Viability and Functionality of Human Cardiomyocytes
por: Rasmussen, Megan L., et al.
Publicado: (2020)

Ubiquitination of HLA-DO by MARCH family E3 ligases
por: Jahnke, Martin, et al.
Publicado: (2013)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
por: Nguyen, Tri, et al.
Publicado: (2018)

The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression
por: Lynch, James T, et al.
Publicado: (2010)

BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis
por: Wensveen, Felix M., et al.
Publicado: (2013)

BH3-Only Proteins Noxa and Puma Are Key Regulators of Induced Apoptosis
por: Roufayel, Rabih, et al.
Publicado: (2022)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

Targeted Delivery of Ubiquitin-Conjugated BH3 Peptide-Based Mcl-1 Inhibitors into Cancer Cells
por: Muppidi, Avinash, et al.
Publicado: (2014)

The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest
por: Haschka, Manuel D., et al.
Publicado: (2015)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Novel regulatory roles of Mff and Drp1 in E3 ubiquitin ligase MARCH5–dependent degradation of MiD49 and Mcl1 and control of mitochondrial dynamics
por: Cherok, Edward, et al.
Publicado: (2017)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

Physiological substrates and ontogeny-specific expression of the ubiquitin ligases MARCH1 and MARCH8
por: Schriek, Patrick, et al.
Publicado: (2021)

Ubiquitin ligase MARCH5 localizes to peroxisomes to regulate pexophagy
por: Zheng, Jun, et al.
Publicado: (2021)

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
por: Wu, Lanqin, et al.
Publicado: (2019)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells
por: Sulkshane, Prasad, et al.
Publicado: (2016)

DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
por: Nakajima, Wataru, et al.
Publicado: (2016)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kr4kc13g72n21mb2u18tig6ivc